ResearcherNational Cancer CenterActive in the last 2 years
Mi Rim Lee
Matched on OpenAlex author ID A5051813522. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 3
- Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study. Co-author DOI 10.3390/cancers17050896↗
- Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Co-author DOI 10.1111/cas.16104↗
- Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment. Co-author DOI 10.1016/j.jconrel.2023.03.048↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yun‐Hee Kim · 3 shared papers, 2023–2025 · strength 0.56
- Paper Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospect… DOI 10.3390/cancers17050896↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment. DOI 10.1016/j.jconrel.2023.03.048↗
- Sang Myung Woo · 3 shared papers, 2023–2025 · strength 0.56
- Paper Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospect… DOI 10.3390/cancers17050896↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment. DOI 10.1016/j.jconrel.2023.03.048↗
- Jung Won Chun · 2 shared papers, 2024–2025 · strength 0.41
- Paper Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospect… DOI 10.3390/cancers17050896↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Woo Jin Lee · 2 shared papers, 2024–2025 · strength 0.41
- Paper Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospect… DOI 10.3390/cancers17050896↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Sun‐Young Kong · 2 shared papers, 2024–2025 · strength 0.41
- Paper Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospect… DOI 10.3390/cancers17050896↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Tae Hyun Kim · 1 shared paper, 2025 · strength 0.22
- Hyeong Min Park · 1 shared paper, 2025 · strength 0.22
- Sung‐Sik Han · 1 shared paper, 2024 · strength 0.19
- Min Kyeong Kim · 1 shared paper, 2024 · strength 0.19
- Sung Yong Choi · 1 shared paper, 2024 · strength 0.19
- Kyong‐Ah Yoon · 1 shared paper, 2024 · strength 0.19
- Sang‐Jae Park · 1 shared paper, 2024 · strength 0.19
- Sun Il Choi · 1 shared paper, 2023 · strength 0.15
- Yu‐Sun Lee · 1 shared paper, 2023 · strength 0.15
- In-Hoo Kim · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.